

Supplementary Appendix

This appendix has been provided by authors to give readers additional information about the work.

Supplement to: Roeder AJ, Lake DF, Koehler MA, et al. SARS-CoV-2 Omicron Variant Infection of Individuals with High Titer Neutralizing Antibodies Post-3rd mRNA Vaccine Dose

A) Pre-December 2021



Age	Sex	1 st /2 nd Dose mRNA Vaccine	Date of 2 nd Dose	Pre-Infection NAb Test	Pre-Infection % Neut. (NAb Titer)	Date of PCR+	NAb Test to PCR+ (days)
46-50	M	BNT162b2	Mar-2021	Sep-2021	84.2 (>1:320)	Sep-2021	8
31-35	M	BNT162b2	Jan-2021	Apr-2021	32.3 (<1:80)	Oct-2021	187
26-30	F	BNT162b2	Jan-2021	Jul-2021	28.5 (<1:80)	Aug-2021	18
61-65	M	BNT162b2	Jan-2021	Aug-2021	25.6 (<1:80)	Sep-2021	20
76-80	F	BNT162b2	Jan-2021	May-2021	21.3 (<1:80)	Jul-2021	61
31-35	F	mRNA-1273	Mar-2021	Sep-2021	20.8 (<1:80)	Nov-2021	40
51-55	M	BNT162b2	Feb-2021	Sep-2021	19.4 (<1:80)	Sep-2021	8
51-55	F	mRNA-1273	Feb-2021	Aug-2021	16.6 (<1:80)	Sep-2021	21
76-80	M	BNT162b2	Feb-2021	May-2021	16.3 (<1:80)	Jul-2021	53
51-55	F	mRNA-1273	Feb-2021	Sep-2021	10.8 (<1:40)	Nov-2021	69
56-60	M	BNT162b2	Feb-2021	Oct-2021	10.1 (<1:40)	Oct-2021	3
81-85	F	BNT162b2	Feb-2021	Sep-2021	7.3 (<1:40)	Oct-2021	23
46-50	F	BNT162b2	Feb-2021	Oct-2021	2.9 (<1:40)	Nov-2021	43
41-45	F	BNT162b2	Mar-2021	Aug-2021	0.0 (<1:40)	Sep-2021	17

B) Post-December 2021

Age	Sex	1 st /2 nd Dose mRNA Vaccine	3 rd Dose mRNA Vaccine	Date of 3 rd Dose	Pre-Infection NAb Test	Pre-Infection % Neut. (NAb Titer)	Date of PCR+	NAb Test to PCR+ (days)
31-35	M	mRNA-1273	mRNA-1273	Nov-2021	Dec-2021	98.9 (>1:640)	Jan-2022	26
61-65	F	BNT162b2	BNT162b2	Oct-2021	Dec-2021	98.8 (>1:640)	Dec-2021	19
56-60	F	BNT162b2	BNT162b2	Oct-2021	Jan-2022	98.8 (>1:640)	Jan-2022	17
46-50	F	BNT162b2	mRNA-1273	Sep-2021	Dec-2021	98.5 (>1:640)	Jan-2022	34
51-55	F	BNT162b2	mRNA-1273	Oct-2021	Dec-2021	98.5 (>1:640)	Jan-2022	27
51-55	F	BNT162b2	BNT162b2	Oct-2021	Dec-2021	98.4 (>1:640)	Jan-2022	20
36-40	F	BNT162b2	mRNA-1273	Nov-2021	Nov-2021	97.4 (>1:640)	Jan-2022	60
46-50	M	BNT162b2	mRNA-1273	Aug-2021	Nov-2021	96.9 (>1:640)	Jan-2022	34
46-50	M	BNT162b2	BNT162b2	Oct-2021	Dec-2021	89.7 (>1:640)	Jan-2022	27
41-45	F	BNT162b2	BNT162b2	Oct-2021	Dec-2021	85.0 (>1:320)	Jan-2022	25
66-70	M	mRNA-1273	mRNA-1273	Oct-2021	Dec-2021	81.6 (>1:320)	Jan-2022	30
61-65	M	BNT162b2	BNT162b2	Aug-2021	Dec-2021	77.6 (>1:160)	Dec-2021	18
41-45	F	BNT162b2	BNT162b2	Oct-2021	Dec-2021	73.4 (>1:160)	Jan-2022	24
36-40	F	mRNA-1273	mRNA-1273	Sep-2021	Jan-2022	67.4 (>1:160)	Jan-2022	6

Supplementary Table S1. (A) Pre- and (B) Post-December 2021 population demographics, vaccination status, and NAb result preceding infection. Age, sex, 1st/2nd vaccine dose and date, 3rd dose vaccine and date (if applicable), date of last NAb test prior to infection, pre-infection NAb result, date of positive PCR for SARS-CoV-2 detection, and days between NAb and PCR dates are detailed in this table. Pre-infection NAb test result is shown as % neutralization, calculated using the limit of detection our rapid NAb lateral flow as described previously.¹ Average age of the pre- and post-December 2021 populations were 54 and 49 (median 55 and 49.5), respectively. Populations in (A) and (B) were 57% and 64% female, respectively.

Supplementary Figure S1 is provided to help orient readers with respect to conversion between units described in the main text, such as NAb LFA test line density, percent neutralization, and NAb titer.

NAb LFA Test Image						
Test Line Density Units (thousands)	10-99	100-199	200-369	370-599	600-799	800-1000
Neutralization (%)	99-90	89-80	79-61	60-36	35-15	≤15
NAb Titer	<1:1280 ≥1:640	<1:640 ≥1:320	<1:320 ≥1:160	<1:160 ≥1:80	<1:80 ≥1:40	≤1:40

Supplementary Figure S1. Neutralizing antibody later flow assay (NAb LFA) measured in density units corresponds to percent neutralization and NAb titer. Validation of the rapid NAb test using gold standard focus reduction neutralization test (FRNT₅₀) with authentic SARS-CoV-2 Wuhan isolate and correlation/regression analyses are previously described.^{1,2}

Supplementary References

1. Lake DF, Roeder AJ, Gonzalez-Moa MJ, Koehler M, Kaleta E, Jasbi P, et al. Third COVID-19 Vaccine Dose Boosts Neutralising Antibodies in Poor Responders. 2021 Dec 2 [accessed 2022 Jan 24]; <http://medrxiv.org/lookup/doi/10.1101/2021.11.30.21266716>
2. Lake DF, Roeder AJ, Kaleta E, Jasbi P, Pfeffer K, Koelbela C, et al. Development of a rapid point-of-care test that measures neutralizing antibodies to SARS-CoV-2. *Journal of Clinical Virology*. 2021 Dec;**145**:105024.